Affimed N V's Comment on Sales, Marketing and Customers
The company serves healthcare markets primarily within the European Union, where healthcare delivery, health services operation, and medicine pricing and reimbursement are regulated by national laws and policies. Budgetary constraints imposed by national governments and health service providers in EU member states limit the pricing and reimbursement of medicines. The company also operates internationally, maintaining supplier relationships and collaborative clinical studies outside the United States. It faces risks associated with economic, political, regulatory, and operational factors in non-U.S. countries, including regulatory differences, intellectual property protection, legal compliance, currency exchange fluctuations, trade barriers, tax laws, labor relations, supply chain disruptions, and geopolitical events.
CSIMarket.com - June 01, 2024: Affimed N.V., a leading clinical-stage immuno-oncology company, has provided updated follow-up data from its AFM24-102 study in non-small cell lung cancer (NSCLC). The data reveal durable responses in heavily pretreated NSCLC patients with EGFR wild-type (EGFRwt) and positive initial clinical efficacy in the NSCLC EGFR mutant (EGFRmut) cohort.:This article aims to present the facts about Affimed s AFM24-102 study, including the longer follow-up data from the EGFRwt cohort and the initial clinical efficacy data from the EGFRmut cohort in NSCLC patients. By interpreting these findings, this article aims to provide an unbiased account of the study s implications for immuno-onco...
Affimed Announces Promising Interim Results for AFM24-102 Study in EGFR Wild-Type NSCLC and Revenue Growth at ASCO 2024 Mannheim, Germany May 23, 2024 Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has shared encouraging early efficacy and progression-free survival (PFS) results from its AFM24-102 study targeting advanced epidermal growth factor receptor (EGFR) wild-type (EGFRwt) non-small cell lung cancer (NSCLC). These interim results were announced ahead of the annual meeting of the American Society of Clinical Oncology (ASCO), scheduled to take place in Chicago from May 31 to June 4, 2024.Affimed s AFM24-102 study showcases a novel therapeutic approach by combining AFM24, an...
Affimed N V’s Comment on Sales, Marketing and Customers
The company serves healthcare markets primarily within the European Union, where healthcare delivery, health services operation, and medicine pricing and reimbursement are regulated by national laws and policies. Budgetary constraints imposed by national governments and health service providers in EU member states limit the pricing and reimbursement of medicines. The company also operates internationally, maintaining supplier relationships and collaborative clinical studies outside the United States. It faces risks associated with economic, political, regulatory, and operational factors in non-U.S. countries, including regulatory differences, intellectual property protection, legal compliance, currency exchange fluctuations, trade barriers, tax laws, labor relations, supply chain disruptions, and geopolitical events.
Sources:
Affimed N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Affimed N v’s corporate clients.
For your research, we’ve provided 9 tables on Affimed N v corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
